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Osteopontin expression and calcium content in
human aortic valves
To the Editor:
The cause or causes of calcific aortic stenosis (CAS)
remain unknown. A number of studies have suggested genet-
ic factors, preexisting rheumatic inflammation, or osteopon-
tin expression.1,2 Osteopontin is a calcium-binding glycopro-
tein ligand of CD44 surface receptor also present in fetal
bone, teeth, and exocrine endothelial cells. The present study
was undertaken to test the hypothesis that osteopontin and
valve calcium content could be related to CAS.
We studied aortic valves from patients undergoing aortic
valve replacement using monoclonal antibodies against
osteopontin and α-smooth muscle actin. In a prospective
study, we evaluated 15 unselected patients aged 22 to 84
years (mean 58.4 years), of whom 10 were women, under-
going aortic valve replacement for valvular stenosis or
regurgitation. Valve specimens were received in the operat-
ing room and preserved in ice during transportation; they
were then stored at –70°C. A portion of the tissue was
removed and fixed in aqueous Bouin solution for immuno-
histochemical study. Total calcium content (in micrograms
per gram of dry tissue) was determined by 7N HNO3 diges-
tion and atomic absorption spectroscopy.
After fixation in Bouin solution, the samples were
embedded in paraffin. Four-micrometer transverse sections
cut on a microtome at room temperature were stained for
osteopontin (MPIIIB10 from the Developmental Studies
Hybridoma Bank, University of Iowa, diluted 1:100, and
Actin 1A4 from Sigma Chemical Company, St Louis, Mo)
with an ABC-peroxidase kit (Vector Laboratories,
Burlingame, Calif) and counterstained with hematoxylin.
Sections were evaluated without knowledge of the tissue
osteopontin expression or calcium content. Ten revealed
calcification. Of these, 5 had fibrous thickening with calci-
fication; the remainder were calcific AS of the senile type,
but the presence of thick-walled vessels suggested postin-
flammatory valve disease. Five patients with uncalcified
valves had fibrotic disruption of cusp architecture, associ-
ated with neovessels with thick muscular walls and few
mononuclear inflammatory cells, consistent with postin-
flammatory (rheumatic) valve disease. Calcium content
was 3091 µmol/g dry tissue (SE = 1048 µmol/g dry tissue)
versus 359 µmol/g dry tissue (SE = 297 µmol/g dry tissue)
(Wilcoxon signed-rank χ2, P = .0004).
Osteopontin expression was present in 9 of 10 calcified
valves and 1 positive fetal femur in a control subject. It was
restricted to the cytoplasm of fibroblast-like spindle cells,
with a paranuclear granular locoalization, probably in the
Golgi area. No osteopontin expression was noted in the 5
patients with uncalcified valves (χ2 = 8.02, P < .005). Mohler
and associates1 reported indentification of osteopontin in
CAS (n = 5) and in noncalcified regurgitant valves (n = 3).
Our results show that osteopontin and Ca2+ are directly asso-
ciated with CAS, results differing from those of Mohler and
colleagues.1 O’Brien and coworkers2 have shown that osteo-
pontin messenger RNA can be produced by macrophages.
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